Literature DB >> 26199716

An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service.

Inti Qurashi1, Paul Stephenson2, Simon Chu1, Chris Duffy1, Nusrat Husain3, Imran Chaudhry4.   

Abstract

OBJECTIVES: Patients prescribed clozapine were surveyed to assess (a) the effects, both positive and adverse, and overall satisfaction with clozapine in comparison to previously prescribed antipsychotics and (b) the relative significance of effects experienced, both positive and adverse, in terms of impact on subjective well-being.
METHODS: A total of 56 male patients prescribed clozapine at a forensic psychiatric hospital were surveyed using a 27-item questionnaire. All patients had been prescribed clozapine for a minimum of 3 months. Respondents were asked to rate effects and satisfaction with clozapine treatment in comparison with previously prescribed antipsychotic medication on a five-point scale. Respondents were also asked to rate effects experienced with clozapine treatment in terms of impact on subjective well-being on a five-point scale.
RESULTS: A total of 89% of respondents reported greater satisfaction with clozapine than with previously prescribed antipsychotic medication. A majority of patients reported positive effects in terms of an improvement in their quality of life (68%) and social abilities (52%) with clozapine in comparison with previously prescribed antipsychotics. Nocturnal hypersalivation (84%) and weight gain (57%) were the most common adverse effects. Hedonic responses were assessed for each effect in order to determine the associated subjective experiences. The most positive hedonic responses were for quality of life, mood and alertness. In terms of adverse impact on subjective well-being, nocturnal hypersalivation ranked highest.
CONCLUSIONS: Patients in a UK forensic sample are largely satisfied with clozapine treatment. The subjective effects of clozapine treatment should be taken into account by clinicians when assessing response. This may provide an opportunity to highlight the positive changes and prioritize management of the most undesirable adverse effects, which is likely to promote compliance and improve longer term treatment outcomes.

Entities:  

Keywords:  clozapine; forensic; side effects; subjective experience

Year:  2015        PMID: 26199716      PMCID: PMC4502588          DOI: 10.1177/2045125315581996

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  16 in total

1.  Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses.

Authors:  K Thompson; J Kulkarni; A A Sergejew
Journal:  Schizophr Res       Date:  2000-05-05       Impact factor: 4.939

2.  Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians.

Authors:  Kay Hodge; Sean Jespersen
Journal:  Int J Ment Health Nurs       Date:  2008-02       Impact factor: 3.503

3.  Patients' and relatives' assessment of clozapine treatment.

Authors:  M C Angermeyer; W Löffler; P Müller; B Schulze; S Priebe
Journal:  Psychol Med       Date:  2001-04       Impact factor: 7.723

4.  Compliance in psychoses.

Authors:  O Kampman; K Lehtinen
Journal:  Acta Psychiatr Scand       Date:  1999-09       Impact factor: 6.392

5.  Novel antipsychotics: comparison of weight gain liabilities.

Authors:  D A Wirshing; W C Wirshing; L Kysar; M A Berisford; D Goldstein; J Pashdag; J Mintz; S R Marder
Journal:  J Clin Psychiatry       Date:  1999-06       Impact factor: 4.384

6.  Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.

Authors:  K Wahlbeck; M Cheine; A Essali; C Adams
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

7.  The Patient Assessment Questionnaire: initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder.

Authors:  Ramin Mojtabai; Patricia K Corey-Lisle; Edward Hak-Sing Ip; Irina Kopeykina; Sophia Haeri; Lisa Janet Cohen; Sally Shumaker
Journal:  Psychiatry Res       Date:  2012-07-26       Impact factor: 3.222

8.  Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection.

Authors:  David M Taylor; Petrina Douglas-Hall; Banke Olofinjana; Eromona Whiskey; Arwel Thomas
Journal:  Br J Psychiatry       Date:  2009-02       Impact factor: 9.319

Review 9.  Patients' subjective experiences of antipsychotics: clinical relevance.

Authors:  Jonathan S E Hellewell
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

10.  Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.

Authors:  Midori Fujikawa; Takashi Togo; Asuka Yoshimi; Junichi Fujita; Munetaka Nomoto; Atsushi Kamijo; Toru Amagai; Hirotake Uchikado; Omi Katsuse; Hideki Hosojima; Yoshihisa Sakura; Ryo Furusho; Akira Suda; Takayuki Yamaguchi; Taketo Hori; Ayuko Kamada; Taizo Kondo; Michitomo Ito; Toshinari Odawara; Yoshio Hirayasu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-12-14       Impact factor: 5.067

View more
  5 in total

1.  Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.

Authors:  Senan Maher; Aoife Cunningham; Niamh O'Callaghan; Fintan Byrne; Colm Mc Donald; Shane McInerney; Brian Hallahan
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-30

Review 2.  Clozapine in Reducing Aggression and Violence in Forensic Populations.

Authors:  Kathleen Patchan; Gopal Vyas; Ann L Hackman; Marie Mackowick; Charles M Richardson; Raymond C Love; Ikwunga Wonodi; MacKenzie A Sayer; Matthew Glassman; Stephanie Feldman; Deanna L Kelly
Journal:  Psychiatr Q       Date:  2018-03

3.  A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.

Authors:  Robert O Cotes; A Umair Janjua; Beth Broussard; David Lazris; Ayesha Khan; Yunshen Jiao; Sarah L Kopelovich; David R Goldsmith
Journal:  Community Ment Health J       Date:  2021-05-29

4.  Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study.

Authors:  Inti Qurashi; Simon Chu; Nusrat Husain; Richard J Drake; Imran Chaudhry; J F W Deakin
Journal:  Trials       Date:  2016-11-21       Impact factor: 2.279

5.  Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): a feasibility study.

Authors:  Inti Qurashi; Simon Chu; Richard Drake; Victoria Hartley; Imran Chaudhry; J F W Deakin; Nusrat Husain
Journal:  Pilot Feasibility Stud       Date:  2019-06-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.